Articles on this page are updated by ProfileData Research on an hourly basis. To see the summary of the SENS notice, please click on the headline. To read the original SENS message, please click on the link in the summary.



Date Headline/Title
11 December 2017Appointment of Babalwa Ngonyama as Chairman of the Audit & Risk Committee
08 December 2017Report on Annual General Meeting Proceedings
06 December 2017Decision not to stand for re-election Maureen Manyama
22 November 2017Aspen Investor Presentation
17 November 2017Dealing in Aspen securities by the Company Secretary of Aspen
07 November 2017Dealing in securities by directors and the company secretary
01 November 2017Further announcement regarding acquisition of residual rights to Astrazeneca anaesthetics portfolio
31 October 2017No Change Statement And Notice Of Annual General Meeting 7 December 2017
19 October 2017Dealing in securities by Directors and Company Secretary
19 October 2017Dealing in Aspen Securities
13 October 2017Investigation By UK Competition Authority
14 September 2017Aspen final results June 2017
08 September 2017Aspens Results for the Year Ended 30 June 2017 and Results Presentation
30 August 2017Trading Statement
14 June 2017Italian Court Ruling on Appeal Oncology Products
14 June 2017Aspens supplementary response to the South African Competition Commission Announcement
13 June 2017South African Competition Commission Announcement
30 May 2017Retraction of Democratic Alliance allegations that Aspen engaged in anti-competitive conduct
15 May 2017Opening of European Commission proceedings
24 April 2017Aspens response to the reported Competition Commission investigation
18 April 2017Aspens response to the press reports of 14 and 15 April 2017
09 March 2017Aspen interim results December 2016
07 March 2017Aspens results for the half-year ended 31 December 2016 and interim results presentation
01 March 2017Trading Statement
01 March 2017Voluntary announcement regarding the completion of a transaction with GSK
03 January 2017Voluntary announcement regarding the completion of transactions with GSK
Powered by ProfileData